Market Place
Sourcing Support
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
13 Nov 2024 //
GLOBENEWSWIRE
Tarsus Reports Q3 & YTD 2024 Results & Achievements
13 Nov 2024 //
GLOBENEWSWIRE
Tarsus to Report Q3 2024 Financials on Nov 13
06 Nov 2024 //
GLOBENEWSWIRE
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
05 Nov 2024 //
GLOBENEWSWIRE
Tarsus Launches First DTC TV Campaign For XDEMVY® Solution
17 Oct 2024 //
GLOBENEWSWIRE
Tarsus’ Xdemvy tackles a ‘mitey problem’ in 1st DTC TV ad
17 Oct 2024 //
FIERCE PHARMA
Tarsus To Participate In UBS Ophthalmology Day 2024
25 Sep 2024 //
GLOBENEWSWIRE
Tarsus To Participate In Wells Fargo Securities Healthcare Conference
28 Aug 2024 //
GLOBENEWSWIRE
Tarsus Reports Strong Xdemvy Launch And Sales Force Expansion
14 Aug 2024 //
FIERCE PHARMA
Tarsus To Report Q2 2024 Financial Results On August 8, 2024
29 Jul 2024 //
GLOBENEWSWIRE
Tarsus to Participate in Upcoming Investor Conferences
29 May 2024 //
GLOBENEWSWIRE
Tarsus To Participate In BofA Healthcare Conference Fireside Chat
09 May 2024 //
GLOBENEWSWIRE
Tarsus Q1 2024 Results, Business Achievements
08 May 2024 //
GLOBENEWSWIRE
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
01 May 2024 //
GLOBENEWSWIRE
Tarsus Refinances Debt With $200M Non-Dilutive Commitment
23 Apr 2024 //
GLOBENEWSWIRE
Tarsus Introduces Mite Party Campaign for XDEMVY
05 Mar 2024 //
GLOBENEWSWIRE
Tarsus to Participate at Upcoming Investor Conferences
05 Mar 2024 //
GLOBENEWSWIRE
Tarsus Announces Pricing of $100.0 Million Public Offering
01 Mar 2024 //
GLOBENEWSWIRE
Tarsus Announces Proposed $100.0 Million Public Offering
29 Feb 2024 //
GLOBENEWSWIRE
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Tarsus Announces Positive Topline Results from Carpo
22 Feb 2024 //
GLOBENEWSWIRE
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results
20 Feb 2024 //
GLOBENEWSWIRE
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Conference
31 Jan 2024 //
GLOBENEWSWIRE
Tarsus Announces Positive Results from the Ersa Phase 2a Trial Evaluating TP-03
11 Dec 2023 //
GLOBENEWSWIRE
Tarsus Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Tarsus to Report Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
Tarsus to Ring Stock Market Closing Bell in Celebration of Launch of XDEMVY
06 Sep 2023 //
GLOBENEWSWIRE
Now Available-XDEMVY, First and Only Approved Treatment for Demodex Blepharitis
24 Aug 2023 //
GLOBENEWSWIRE
Tarsus Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Stock
01 Aug 2023 //
GLOBENEWSWIRE
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares
31 Jul 2023 //
GLOBENEWSWIRE
FDA clears Tarsus` Xdemvy as first treatment for common eyelid disease
26 Jul 2023 //
FIERCE PHARMA
Why Shares of Tarsus Pharmaceuticals Are Up Thursday
20 Jul 2023 //
FOOL
Tarsus Surges 7.8%: Is This an Indication of Further Gains?
20 Jul 2023 //
YAHOO FINANCE
Tarsus Reports First Quarter 2023 Financial Results
12 Jun 2023 //
PRESS RELEASE
Tarsus to Host Investor Webcast Highlighting Plans and Progress for TP-03
12 Jun 2023 //
GLOBENEWSWIRE
Tarsus to Present at the Jefferies Global Healthcare Conference
05 Jun 2023 //
GLOBENEWSWIRE
Tarsus Reports1Q 2023 FYR and Recent Business Achievements
09 May 2023 //
GLOBENEWSWIRE
Tarsus issues `call to action` months before FDA decision on eye mite treatment
09 May 2023 //
ENDPTS
Tarsus Launches œDon™t Freak Out. Get Checked Out Campaign During Healthy Vision
08 May 2023 //
GLOBENEWSWIRE
Tarsus to Participate at the Bank of America 2023 Healthcare Conference
03 May 2023 //
GLOBENEWSWIRE
Tarsus Appoints Jeff Farrow as Chief Financial Officer and CSO
24 Apr 2023 //
GLOBENEWSWIRE
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
13 Mar 2023 //
GLOBENEWSWIRE
Tarsus to Present at Upcoming Investor Conferences
02 Mar 2023 //
GLOBENEWSWIRE
Tarsus Added to NASDAQ Biotechnology Index
16 Dec 2022 //
GLOBENEWSWIRE
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial
15 Dec 2022 //
GLOBENEWSWIRE
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at Meeting
25 Oct 2022 //
GLOBENEWSWIRE
Tarsus Announces Transition Plans for Board of Directors
11 Oct 2022 //
GLOBENEWSWIRE
Tarsus launches ‘Look at the Lids’ campaign for painful eyelid condition
30 Sep 2022 //
FIERCEPHARMA
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals
29 Sep 2022 //
GLOBENEWSWIRE
Tarsus looks to raise awareness of eyelid mite disease in campaign
29 Sep 2022 //
ENDPTS
Tarsus to Present Saturn-2 Pivotal Ph3 Trial Data and Saturn-1 Extension Study
27 Sep 2022 //
GLOBENEWSWIRE
Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment
07 Sep 2022 //
GLOBENEWSWIRE
Tarsus Reports Q2 2022 Rusult and Recent Business Achievements
11 Aug 2022 //
GLOBENEWSWIRE
Tarsus Initiates PIIa Ersa Trial Evaluating TP-03 for Meibomian Gland Disease
05 Aug 2022 //
GLOBENEWSWIRE
Tarsus to Present at the Jefferies 2022 Healthcare Conference
27 May 2022 //
GLOBENEWSWIRE
Tarsus Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Tarsus to Present at Bank of America 2022 Healthcare Conference
06 May 2022 //
GLOBENEWSWIRE
Tarsus Presents New Findings from Two Studies on Demodex Blepharitis at ARVO
05 May 2022 //
GLOBENEWSWIRE
Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering
03 May 2022 //
GLOBENEWSWIRE
